REG - Ondine Biomedical - Result of AGM and Voting Results

Ondine BiomedicalAnnouncement

28/06/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240628:nRSb4565Ua&default-theme=true

RNS Number : 4565U  Ondine Biomedical Inc.  28 June 2024

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Result of AGM and voting results

Ondine Biomedical (AIM: OBI) announces that at its Annual General Meeting held
on 28 June 2024 all resolutions were duly passed.

The voting results of the AGM were as follows:

                             In Favor             Against      Withheld
 Resolution                  Votes        %       Votes  %     Votes
 1. Election of Directors
 Carolyn Cross               191,380,245  100.00  0      0.00  0
 Nicolas G. Loebel           191,380,245  100.00  0      0.00  0
 Jean Charest                190,741,872  99.67   0      0.00  638,373
 Jean Duvall                 190,741,872  99.67   0      0.00  638,373
 Junaid Bajwa                190,741,872  99.67   0      0.00  638,373
 Michael Farrar              190,741,872  99.67   0      0.00  638,373
 Craig Tooman                190,741,872  99.67   0      0.00  638,373
 2. Appointment of Auditors  191,380,245  100.00  0      0.00  0

 

Enquiries:

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                           +001 (604) 665 0555

 Singer Capital Markets

(Nominated Adviser and Joint Broker)
 Aubrey Powell, Sam Butcher, Jalini Kalaravy  +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard             +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a clinical Canadian life sciences company and leader
in light-activated antimicrobial therapies (also known as
'photodisinfection'). Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection technology, in various stages of
development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe, the UK-CA
mark, and is approved in Canada and several other countries under the name
Steriwave(®). In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEAKKPADNLEFA